Molecular Partners has developed the DARPin platform as a fast and robust product engine for generating new protein drugs that have the potential to transform medicine. In more than 50 cases, DARPins with very high potency, affinity for a target and strong biophysical profiles have been identified. A robust process ensures that DARPins with properties allowing preclinical and clinical development can be identified at unmatched speed.
Each DARPin drug candidate can profit from the distinct class behavior, including:
- very high affinity and potency, often in the low picomolar range
- exceptional stability and solubility
- simple and low-cost production
- tailored PK profile, ranging from minutes to a week
- formating for multiple specificities and effector functions
- high safety and absence of T-cell epitopes for low risk of immunogenicity